Fluoxetine is a potent inhibitor of coxsackievirus replication

A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847 · see citing works

Enterovirus Surveillance - United States, 1970-2005: (540562006-001)

Khetsuriani, N., LaMonte-Fowlkes, A., Oberste, M. S., & Pallansch, M. A. (2006) · PsycEXTRA Dataset · doi:10.1037/e540562006-001 · Cited by 702 · see citing works

Molecular Epidemiology and Evolution of Enterovirus 71 Strains Isolated from 1970 to 1998

Brown, B. A., Oberste, M. S., Alexander, J. P., Kennett, M., & Pallansch, M. A. (1999) · Journal of Virology · doi:10.1128/jvi.73.12.9969-9975.1999 · Cited by 431 · see citing works

Use of Selective Serotonin Reuptake Inhibitors and Risk of Upper Gastrointestinal Tract Bleeding: A Population-Based Cohort Study

Dalton, S. O., Johansen, C., Mellemkjær, L., Sørensen, H. T., Nørgård, B., & Olsen, J. H. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.1.59 · Cited by 389 · see citing works

Treatment of Potentially Life-Threatening Enterovirus Infections with Pleconaril

Rotbart, H. A., Webster, A., & for the Pleconaril Treatment Registry Group (2001) · Clinical Infectious Diseases · doi:10.1086/318452 · Cited by 373 · see citing works

Textbook of Pediatric Infectious Diseases,

Hanshaw, J. B. (1981) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.1981.02130350074027 · Cited by 278 · see citing works

Molecular Epidemiology of Human Enterovirus 71 Strains and Recent Outbreaks in the Asia-Pacific Region: Comparative Analysis of the VP1 and VP4 Genes

Cardosa, M. J., Perera, D., Brown, B. A., Cheon, D., Chan, H. M., Chan, K. P., Cho, H., & McMinn, P. C. (2003) · Emerging infectious diseases · doi:10.3201/eid0904.020395 · Cited by 272 · see citing works

A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3

Knowlton, K. U., Jeon, E., Berkley, N., Wessely, R., & Huber, S. A. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.7811-7818.1996 · Cited by 261 · see citing works

Evidence for Frequent Recombination within SpeciesHuman Enterovirus BBased on Complete Genomic Sequences of All Thirty-Seven Serotypes

Oberste, M. S., Maher, K., & Pallansch, M. A. (2003) · Journal of Virology · doi:10.1128/jvi.78.2.855-867.2004 · Cited by 258 · see citing works

Selective inhibitors of picornavirus replication

Palma, A. M. D., Vliegen, I., Clercq, E. D., & Neyts, J. H. (2008) · Medicinal Research Reviews · doi:10.1002/med.20125 · Cited by 258 · see citing works

Host and virus determinants of picornavirus pathogenesis and tropism

Whitton, J. L., Cornell, C. T., & Feuer, R. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1284 · Cited by 249 · see citing works

Fluoxetine: clinical pharmacology and physiologic disposition.

Lemberger, L., Bergstrom, R. F., Wolen, R. L., Farid, N. A., Enas, G. G., & Aronoff, G. R. (1985) · PubMed · Cited by 196 · see citing works

An outbreak of enterovirus 71 infection in Taiwan, 1998: epidemiologic and clinical manifestations

Liu, C., Tseng, H., Wang, S., Wang, J., & Su, I. (2000) · Journal of Clinical Virology · doi:10.1016/s1386-6532(00)00068-8 · Cited by 183 · see citing works

Cell Cycle Status Affects Coxsackievirus Replication, Persistence, and Reactivation In Vitro

Feuer, R., Mena, I., Pagarigan, R. R., Slifka, M. K., & Whitton, J. L. (2002) · Journal of Virology · doi:10.1128/jvi.76.9.4430-4440.2002 · Cited by 183 · see citing works

Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll‐like receptors

Sacre, S. M., Medghalchi, M., Gregory, B., Brennan, F. M., & Williams, R. O. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27304 · Cited by 182 · see citing works

Characterization of the Nucleoside Triphosphatase Activity of Poliovirus Protein 2C Reveals a Mechanism by Which Guanidine Inhibits Poliovirus Replication

Pfister, T. D., & Wimmer, E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.11.6992 · Cited by 180 · see citing works

Synchronous replication of poliovirus RNA: initiation of negative-strand RNA synthesis requires the guanidine-inhibited activity of protein 2C

Barton, D. J., & Flanegan, J. B. (1997) · Journal of Virology · doi:10.1128/jvi.71.11.8482-8489.1997 · Cited by 171 · see citing works

Combating enterovirus replication: State-of-the-art on antiviral research

Thibaut, H. J., Palma, A. M. D., & Neyts, J. H. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.08.016 · Cited by 159 · see citing works

Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction

Labos, C., Dasgupta, K., Nedjar, H., Turecki, G., & Rahme, E. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.100912 · Cited by 159 · see citing works

Toward Testing the Hypothesis that Group B Coxsackieviruses (CVB) Trigger Insulin-Dependent Diabetes: Inoculating Nonobese Diabetic Mice with CVB Markedly Lowers Diabetes Incidence

Tracy, S., Drescher, K. M., Chapman, N. M., Kim, K., Carson, S. D., Pirruccello, S. J., Lane, P. H., Romero, J. R., & Leser, J. S. (2002) · Journal of Virology · doi:10.1128/jvi.76.23.12097-12111.2002 · Cited by 158 · see citing works

A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder.

Chouinard, G. (1985) · PubMed · Cited by 157 · see citing works

RNA Recombination Plays a Major Role in Genomic Change during Circulation of Coxsackie B Viruses

Oberste, M. S., Peñaranda, S., & Pallansch, M. A. (2004) · Journal of Virology · doi:10.1128/jvi.78.6.2948-2955.2004 · Cited by 137 · see citing works

Predictors and treatment strategies of HIV-related fatigue in the combined antiretroviral therapy era

Jong, E., Oudhoff, L. A., Epskamp, C., Wagener, M. N., van Duijn, M., Fischer, S., & van Gorp, E. C. (2010) · AIDS · doi:10.1097/qad.0b013e328339d004 · Cited by 116 · see citing works

Development and evaluation of a ‘real‐time’ RT‐PCR for the detection of enterovirus and parechovirus RNA in CSF and throat swab samples

Corless, C. E., Guiver, M., Borrow, R., Edwards-Jones, V., Fox, A. J., Kaczmarski, E. B., & Mutton, K. J. (2002) · Journal of Medical Virology · doi:10.1002/jmv.10138 · Cited by 106 · see citing works

Fluoxetine: a review of receptor and functional effects and their clinical implications

Beasley, C. M., Masica, D. N., & Potvin, J. H. (1992) · Psychopharmacology · doi:10.1007/bf02244958 · Cited by 100 · see citing works

The enterovirus 71 epidemic in 2008—public health implications for Hong Kong

Ma, E., Chan, K. C., Cheng, P. K. C., Wong, C., & Chuang, S. K. (2010) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2010.02.2265 · Cited by 97 · see citing works

Using Recombinant Coxsackievirus B3 To Evaluate the Induction and Protective Efficacy of CD8+T Cells during Picornavirus Infection

Slifka, M. K., Pagarigan, R. R., Mena, I., Feuer, R., & Whitton, J. L. (2001) · Journal of Virology · doi:10.1128/jvi.75.5.2377-2387.2001 · Cited by 95 · see citing works

Increased Activity of Coxsackievirus B1 Strains Associated with Severe Disease among Young Infants in the United States, 2007–2008

Wikswo, M. E., Khetsuriani, N., Fowlkes, A. L., Zheng, X., Peñaranda, S., Verma, N., Shulman, S. T., Sircar, K. D., Robinson, C. C., Schmidt, T., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/605090 · Cited by 88 · see citing works

Outbreak of Life‐Threatening Coxsackievirus B1 Myocarditis in Neonates

Verma, N. A., Zheng, X., Harris, M. U., Cadichon, S. B., Melín‐Aldana, H., Khetsuriani, N., Oberste, M. S., & Shulman, S. T. (2009) · Clinical Infectious Diseases · doi:10.1086/605089 · Cited by 86 · see citing works

Rapid identification of inhibitors that interfere with poliovirus replication using a cell-based assay

HWANG, Y., Chu, J. J. H., Yang, P. L., CHEN, W., & YATES, M. (2008) · Antiviral Research · doi:10.1016/j.antiviral.2007.12.009 · Cited by 82 · see citing works

Nonpolio Enterovirus and Human Parechovirus Surveillance—United States, 2006-2008

(2011) · JAMA · doi:10.1001/jama.2011.461 · Cited by 73 · see citing works

Abnormal Platelet Aggregation Associated with Fluoxetine Therapy

Alderman, C., Moritz, C. K., & Ben-Tovim, D. I. (1992) · Annals of Pharmacotherapy · doi:10.1177/106002809202601205 · Cited by 68 · see citing works

Lycorine: a eukaryotic termination inhibitor?

Vrijsen, R., Berghe, D. A. V., Vlietinck, A. J., & Boeyé, A. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36118-5 · Cited by 65 · see citing works

MicroRNA in the regulation and expression of serotonergic transmission in the brain and other tissues

Millan, M. J. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.01.008 · Cited by 63 · see citing works

An Investigation of Epidemic Enterovirus 71 Infection in Taiwan, 2008

Lee, M.-S., Lin, T., Chiang, P.-S., Li, W.-C., Luo, S.-T., Tsao, K., Liou, G.-Y., Huang, M.-L., Hsia, S., Huang, Y., et al. (2010) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181e52945 · Cited by 60 · see citing works

Towards the design of combination therapy for the treatment of enterovirus infections

Thibaut, H. J., Leyssen, P., Puerstinger, G., Muigg, A., Neyts, J. H., & Palma, A. M. D. (2011) · Antiviral Research · doi:10.1016/j.antiviral.2011.03.187 · Cited by 57 · see citing works

Nonpolio enterovirus and human parechovirus surveillance --- United States, 2006-2008.

(2010) · PubMed · Cited by 48 · see citing works

Degradation of cellular proteins during poliovirus infection: studies by two-dimensional gel electrophoresis

Urzainqui, A., & Carrasco, L. (1989) · Journal of Virology · doi:10.1128/jvi.63.11.4729-4735.1989 · Cited by 47 · see citing works

Increased Detections and Severe Neonatal Disease Associated With Coxsackievirus B1 Infection—United States, 2007

(2008) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e318184ef67 · Cited by 47 · see citing works

Cell cycle regulation of hepatitis C and encephalomyocarditis virus internal ribosome entry site-mediated translation in human embryonic kidney 293 cells

Venkatesan, A., Sharma, R. D., & Dasgupta, A. (2003) · Virus Research · doi:10.1016/s0168-1702(03)00136-9 · Cited by 35 · see citing works

Enteroviruses and Parechoviruses

Stellrecht, K. A., Lamson, D. M., & Romero, J. R. (2011) · doi:10.1128/9781555816728.ch85 · Cited by 34 · see citing works

Comparative Genomics of the Coxsackie B Viruses and Related Enteroviruses

Oberste, M. S. (2008) · Springer eBooks · doi:10.1007/978-3-540-75546-3_2 · Cited by 28 · see citing works

Psychotropic drug effects on gene transcriptomics relevant to Parkinson's disease

Lauterbach, E. C. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.03.011 · Cited by 23 · see citing works

Fatal Neonatal Myocarditis Caused by a Recombinant Human Enterovirus-B Variant

Krogstad, P. A., Hammon, R. J., Halnon, N. J., & Whitton, J. L. (2008) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31816b5d2a · Cited by 22 · see citing works

Development of robust antiviral assays for profiling compounds against a panel of positive-strand RNA viruses using ATP/luminescence readout

Gong, E. Y., Ivens, T., den Eynde, C. V., Hallenberger, S., & Hertogs, K. (2008) · Journal of Virological Methods · doi:10.1016/j.jviromet.2008.03.012 · Cited by 19 · see citing works

Choline-Binding Proteins

Swiatlo, E., McDaniel, L. S., & Briles, D. E. (2014) · ASM Press eBooks · doi:10.1128/9781555816537.ch4 · Cited by 18 · see citing works

Packaging limits and stability of HIV-1 sequences in a coxsackievirus B vector

Miller, J. P., Geng, Y., Ng, H. L., Yang, O. O., & Krogstad, P. A. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.035 · Cited by 15 · see citing works

Fluoxetine Disposition in Patients with Chronic Hepatitis C Treated with Interferon-α

Furlanut, M., Soardo, G., Donnini, D., Sechi, L. A., & Franceschi, L. (2010) · Clinical Pharmacokinetics · doi:10.2165/11534720-000000000-00000 · Cited by 5 · see citing works

The life cycle of non-polio enteroviruses and how to target it

Baggen, J., Thibaut, H. J., Strating, J. R. P. M., & van Kuppeveld, F. J. M. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0005-4 · Cited by 483 · see citing works

Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19

Sukhatme, V., Reiersen, A. M., Vayttaden, S. J., & Sukhatme, V. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.652688 · Cited by 178 · see citing works

Human induced pluripotent stem cell–derived cardiomyocytes as an in vitro model for coxsackievirus B3–induced myocarditis and antiviral drug screening platform

Sharma, A., Marceau, C., Hamaguchi, R., Burridge, P. W., Rajarajan, K., Churko, J. M., Wu, H., Sallam, K. I., Matsa, E., Sturzu, A. C., et al. (2014) · Circulation Research · doi:10.1161/circresaha.115.303810 · Cited by 148 · see citing works

Enteroviruses in the early 21st century

Lugo, D. J., & Krogstad, P. A. (2015) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000303 · Cited by 144 · see citing works

Persistent coxsackievirus B infection and pathogenesis of type 1 diabetes mellitus

Nekoua, M. P., Alidjinou, E. K., & Hober, D. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00688-1 · Cited by 141 · see citing works

Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants

Oskotsky, T., Marić, I., Tang, A., Oskotsky, B., Wong, R. J., Aghaeepour, N., Sirota, M., & Stevenson, D. K. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.33090 · Cited by 131 · see citing works

Recent progress in understanding coxsackievirus replication, dissemination, and pathogenesis

Sin, J., Mangale, V., Thienphrapa, W., Gottlieb, R. A., & Feuer, R. (2015) · Virology · doi:10.1016/j.virol.2015.06.006 · Cited by 106 · see citing works

Selective Serotonin Reuptake Inhibitor Fluoxetine Inhibits Replication of Human Enteroviruses B and D by Targeting Viral Protein 2C

Ulferts, R., van der Linden, L., Thibaut, H. J., Lanke, K. H. W., Leyssen, P., Coutard, B., Palma, A. M. D., Canard, B., Neyts, J. H., & van Kuppeveld, F. J. M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02084-12 · Cited by 102 · see citing works

Direct-acting antivirals and host-targeting strategies to combat enterovirus infections

Bauer, L., Lyoo, H., van der Schaar, H. M., Strating, J. R. P. M., & van Kuppeveld, F. J. M. (2017) · Current Opinion in Virology · doi:10.1016/j.coviro.2017.03.009 · Cited by 95 · see citing works

Enteroviruses in X-Linked Agammaglobulinemia: Update on Epidemiology and Therapy

Bearden, D. R., Collett, M. S., Quan, P. L., Costa‐Carvalho, B. T., & Sullivan, K. E. (2016) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2015.12.015 · Cited by 91 · see citing works

Identification of Luteolin as Enterovirus 71 and Coxsackievirus A16 Inhibitors through Reporter Viruses and Cell Viability-Based Screening

Xu, L., Su, W., Jin, J., Chen, J., Li, X., Zhang, X., Sun, M., Sun, S., Fan, P., An, D., et al. (2014) · Viruses · doi:10.3390/v6072778 · Cited by 87 · see citing works

Enterovirus D68 Antivirals: Past, Present, and Future

Hu, Y., Musharrafieh, R. G., Zheng, M., & Wang, J. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00120 · Cited by 81 · see citing works

Screening of a Library of FDA-Approved Drugs Identifies Several Enterovirus Replication Inhibitors That Target Viral Protein 2C

Ulferts, R., de Boer, S. M., van der Linden, L., Bauer, L., Lyoo, H., Maté, M. J., Lichière, J., Canard, B., Lelieveld, D., Omta, W. A., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02182-15 · Cited by 79 · see citing works

Fluoxetine Inhibits Enterovirus Replication by Targeting the Viral 2C Protein in a Stereospecific Manner

Bauer, L., Manganaro, R., Zonsics, B., Strating, J. R. P. M., Kazzi, P. E., Lopez, M. L., Ulferts, R., van Hoey, C., Maté, M. J., Langer, T., et al. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00179 · Cited by 78 · see citing works

Widely available lysosome targeting agents should be considered as potential therapy for COVID-19

Homolak, J., & Kodvanj, I. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106044 · Cited by 75 · see citing works

Enterovirus Persistence in Cardiac Cells of Patients With Idiopathic Dilated Cardiomyopathy Is Linked to 5’ Terminal Genomic RNA-Deleted Viral Populations With Viral-Encoded Proteinase Activities

Bouin, A., Gretteau, P.-A., Wehbe, M., Renois, F., N’Guyen, Y., Lévêque, N., Vu, M. N., Tracy, S., Chapman, N. M., Bruneval, P., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.035966 · Cited by 73 · see citing works

Acute Flaccid Paralysis and Enteroviral Infections

Bitnun, A., & Yeh, E. A. (2018) · Current Infectious Disease Reports · doi:10.1007/s11908-018-0641-x · Cited by 73 · see citing works

Rationale for the Evaluation of Fluoxetine in the Treatment of Enterovirus D68-Associated Acute Flaccid Myelitis

Tyler, K. L. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4625 · Cited by 67 · see citing works

Project IDentif.AI: Harnessing Artificial Intelligence to Rapidly Optimize Combination Therapy Development for Infectious Disease Intervention

Abdulla, A., Wang, B., Feng, Q., Kee, T. W., Blasiak, A., Ong, Y. H., Hooi, L., Parekh, F. K., Soriano, R., Olinger, G. G., et al. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000034 · Cited by 65 · see citing works

Synthesis and Structure–Activity Relationship (SAR) Studies of Novel Pyrazolopyridine Derivatives as Inhibitors of Enterovirus Replication

Xing, Y., Zuo, J., Krogstad, P. A., & Jung, M. E. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01863 · Cited by 65 · see citing works

Treatment of Chronic Enterovirus Encephalitis With Fluoxetine in a Patient With X-Linked Agammaglobulinemia

Gofshteyn, J. S., Cárdenas, A. M., & Bearden, D. R. (2016) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2016.06.014 · Cited by 59 · see citing works

Antimicrobial Properties of Antidepressants and Antipsychotics—Possibilities and Implications

Caldara, M., & Marmiroli, N. (2021) · Pharmaceuticals · doi:10.3390/ph14090915 · Cited by 54 · see citing works

Identification of dibucaine derivatives as novel potent enterovirus 2C helicase inhibitors: In vitro, in vivo, and combination therapy study

Tang, Q., Xu, Z., Jin, M., Shu, T., Chen, Y., Feng, L., Zhang, Q., Lan, K., Wu, S., & Zhou, H. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112310 · Cited by 48 · see citing works

Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives?

Pashaei, Y. (2021) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2021.03.010 · Cited by 46 · see citing works

Is Autophagy Involved in the Diverse Effects of Antidepressants?

Rein, T. (2019) · Cells · doi:10.3390/cells8010044 · Cited by 45 · see citing works

Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort

Clelland, C. L. T., Ramiah, K., Steinberg, L. J., & Clelland, J. D. (2021) · BJPsych Open · doi:10.1192/bjo.2021.1053 · Cited by 45 · see citing works

Fluoxetine Can Inhibit SARS-CoV-2 In Vitro

Dechaumes, A., Nekoua, M. P., Belouzard, S., Sané, F., Engelmann, I., Dubuisson, J., Alidjinou, E. K., & Hober, D. (2021) · Microorganisms · doi:10.3390/microorganisms9020339 · Cited by 42 · see citing works

Fluoxetine targets an allosteric site in the enterovirus 2C AAA+ ATPase and stabilizes a ring-shaped hexameric complex

Hurdiss, D. L., Kazzi, P. E., Bauer, L., Papageorgiou, N., Ferrón, F., Donselaar, T., van Vliet, A. L. W., Shamorkina, T. M., Snijder, J., Canard, B., et al. (2022) · Science Advances · doi:10.1126/sciadv.abj7615 · Cited by 41 · see citing works

Crystal structure of a soluble fragment of poliovirus 2CATPase

Guan, H., Tian, J., Zhang, C., Qin, B., & Cui, S. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1007304 · Cited by 41 · see citing works

Can selective serotonin reuptake inhibitors have a neuroprotective effect during COVID-19?

da Costa, L. H. A., Santos, B. M., & Branco, L. G. S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173629 · Cited by 39 · see citing works

Drugs that offer the potential to reduce hospitalization and mortality from SARS-CoV-2 infection: The possible role of the sigma-1 receptor and autophagy

Brimson, J. M., Prasanth, M. I., Malar, D. S., Brimson, S. J., Thitilertdecha, P., & Tencomnao, T. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1952987 · Cited by 36 · see citing works

Rational design of highly potent broad-spectrum enterovirus inhibitors targeting the nonstructural protein 2C

Bauer, L., Manganaro, R., Zonsics, B., Hurdiss, D. L., Zwaagstra, M., Donselaar, T., Welter, N. G. E., van Kleef, R. G. D. M., Lopez, M. L., Bevilacqua, F., et al. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000904 · Cited by 36 · see citing works

N -Desmethylclozapine, Fluoxetine, and Salmeterol Inhibit Postentry Stages of the Dengue Virus Life Cycle

Medigeshi, G. R., Kumar, R., Dhamija, E., Agrawal, T., & Kar, M. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01367-16 · Cited by 35 · see citing works

Recent advances on the role of host factors during non-poliovirus enteroviral infections

Owino, C. O., & Chu, J. J. H. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0540-y · Cited by 34 · see citing works

Persistent infection of human pancreatic cells with Coxsackievirus B4 is cured by fluoxetine

Alidjinou, E. K., Sané, F., Bertin, A., Caloone, D., & Hober, D. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.01.010 · Cited by 34 · see citing works

Synthesis and antiviral effect of novel fluoxetine analogues as enterovirus 2C inhibitors

Manganaro, R., Zonsics, B., Bauer, L., Lopez, M. L., Donselaar, T., Zwaagstra, M., Saporito, F., Ferla, S., Strating, J. R. P. M., Coutard, B., et al. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104781 · Cited by 29 · see citing works

Structural Chemistry of Helicase Inhibition

Selvaratnam, L., Willson, T. M., & Schapira, M. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01909 · Cited by 28 · see citing works

Fluoxetine can inhibit coxsackievirus-B4 E2 in vitro and in vivo

Benkahla, M. A., Alidjinou, E. K., Sané, F., Desailloud, R., & Hober, D. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.10.002 · Cited by 27 · see citing works

Combating coxsackievirus B infections

Alhazmi, A., Nekoua, M. P., Mercier, A., Vergez, I., Sané, F., Alidjinou, E. K., & Hober, D. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2406 · Cited by 28 · see citing works

Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5

Loddo, R., Novelli, F., Sparatore, A., Tasso, B., Tonelli, M., Boido, V., Sparatore, F., Collu, G., Delogu, I., Giliberti, G., et al. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.09.035 · Cited by 27 · see citing works

Fluoxetine a novel anti-hepatitis C virus agent via ROS-, JNK-, and PPARβ/γ-dependent pathways

Young, K.-C., Bai, C., Su, H., Tsai, P., Pu, C.-Y., Liao, C., Lin, Y., Lai, H.-W., Chong, L.-W., Tsai, Y.-S., et al. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.08.002 · Cited by 25 · see citing works

Discovery of Structurally Diverse Small-Molecule Compounds with Broad Antiviral Activity against Enteroviruses

Zuo, J., Kye, S., Quinn, K. K., Cooper, P., Damoiseaux, R. D., & Krogstad, P. A. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02646-15 · Cited by 24 · see citing works

Fluoxetine pharmacokinetics and tissue distribution quantitatively supports a therapeutic role in COVID-19 at a minimum dose of 20 mg per day

Eugene, A. R. (2021) · F1000Research · doi:10.12688/f1000research.53275.1 · Cited by 22 · see citing works

Direct-Acting Antivirals and Host-Targeting Approaches against Enterovirus B Infections: Recent Advances

Tammaro, C., Guida, M., Appetecchia, F., Biava, M., Consalvi, S., & Poce, G. (2023) · Pharmaceuticals · doi:10.3390/ph16020203 · Cited by 21 · see citing works

Therapeutic targets for enterovirus infections

Laajala, M., Reshamwala, D., & Marjomäki, V. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1784141 · Cited by 19 · see citing works

Screening and identification of inhibitors against influenza A virus from a US drug collection of 1280 drugs

An, L., Liu, R., Tang, W. F., Wu, J., & Chen, X. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.06.007 · Cited by 19 · see citing works

Quantum tunnelling in the context of SARS-CoV-2 infection

Adams, B., Sinayskiy, I., van Grondelle, R., & Petruccione, F. (2022) · Scientific Reports · doi:10.1038/s41598-022-21321-1 · Cited by 16 · see citing works

Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use

Foletto, V. S., da Rosa, T. F., Serafin, M. B., & Hörner, R. (2022) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-022-03372-5 · Cited by 16 · see citing works

Compassionate-use pocapavir and immunoglobulin therapy for treatment of rituximab-associated enterovirus meningoencephalitis

Epstein, S., Thakkar, R., Fong, K. T., Ng, J., Bearden, D. R., Mishra, N., Thakur, K. T., & Riley, C. (2022) · Journal of NeuroVirology · doi:10.1007/s13365-021-01038-z · Cited by 15 · see citing works

Treatment of rituximab-associated chronic CNS enterovirus using IVIg and fluoxetine

Sham, L., Bitnun, A., Branson, H. M., Hazrati, L., Dell, S., Yeung, R. S. M., Johnstone, J., & Yeh, E. A. (2019) · Neurology · doi:10.1212/wnl.0000000000007468 · Cited by 14 · see citing works

Eradication of persistent coxsackievirus B infection from a pancreatic cell line with clinically used antiviral drugs

Honkimaa, A., Sioofy‐Khojine, A., Oikarinen, S., Bertin, A., Hober, D., & Hyöty, H. (2020) · Journal of Clinical Virology · doi:10.1016/j.jcv.2020.104334 · Cited by 14 · see citing works

The Current Recommended Drugs and Strategies for the Treatment of Coronavirus Disease (COVID-19)

Sheikhpour, M. (2020) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s262936 · Cited by 13 · see citing works

Structure Prediction and Potential Inhibitors Docking of Enterovirus 2C Proteins

Li, D., & Zhang, L. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.856574 · Cited by 10 · see citing works

Fighting Enteroviral Infections to Prevent Type 1 Diabetes

Nekoua, M. P., Mercier, A., Alhazmi, A., Sané, F., Alidjinou, E. K., & Hober, D. (2022) · Microorganisms · doi:10.3390/microorganisms10040768 · Cited by 10 · see citing works

An Overview of Fluvoxamine and its Use in SARS-CoV-2 Treatment

Arishi, N. A., Althomali, N., Dighriri, I. M., AlHarthi, M. S., Alqurashi, G. B., Musharraf, R. A., Albuhayri, A. H., Almalki, M. K., Alnami, S. A., & Mashraqi, Z. O. (2023) · Cureus · doi:10.7759/cureus.34158 · Cited by 10 · see citing works

Myocarditis, Disseminated Infection, and Early Viral Persistence Following Experimental Coxsackievirus B Infection of Cynomolgus Monkeys

Cammock, C. E., Halnon, N. J., Skoczylas, J., Blanchard, J., Bohm, R. P., Miller, C. J., Lai, C. K., & Krogstad, P. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074569 · Cited by 10 · see citing works

Acute Flaccid Myelitis: Characteristics and Outcomes of 2014 and 2016 Cases at a Single Center

Matesanz, S. E., McGuire, J. L., & Hopkins, S. E. (2019) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2019.07.015 · Cited by 10 · see citing works

Picornaviral 2C proteins: A unique ATPase family critical in virus replication

Chen, P., Li, Z., & Cui, S. (2021) · The Enzymes · doi:10.1016/bs.enz.2021.06.008 · Cited by 9 · see citing works

Automated cell-based luminescence assay for profiling antiviral compound activity against enteroviruses

Zhang, M., Zhang, Y., Wang, Y., Lv, W., & Zhang, Y. (2019) · Scientific Reports · doi:10.1038/s41598-019-42160-7 · Cited by 9 · see citing works

Research progress and application prospects of animal models of group B Coxsackievirus infections

Weng, S., Zhu, R., Wu, Y., Xia, N., Xu, L., & Cheng, T. (2024) · Emerging Microbes & Infections · doi:10.1080/22221751.2024.2441391 · Cited by 8 · see citing works

Selective serotonin reuptake inhibitors: New hope in the fight against COVID-19

Anar, M. A., Foroughi, E., Sohrabi, E., Peiravi, S., Tavakoli, Y., Khouzani, M. K., Behshood, P., Shamshiri, M., Faridzadeh, A., Keylani, K., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1036093 · Cited by 11 · see citing works

Fluoxetine pharmacokinetics and tissue distribution quantitatively supports a therapeutic role in COVID-19 at a minimum dose of 20 mg per day

Eugene, A. R. (2022) · F1000Research · doi:10.12688/f1000research.53275.2 · Cited by 7 · see citing works

Psychotropics and COVID-19: An analysis of safety and prophylaxis

Javelot, H., Straczek, C., Meyer, G., Faria, C. G. F., Weiner, L., Drapier, D., Fakra, É., Fossati, P., Weibel, S., Dizet, S., et al. (2021) · L Encéphale · doi:10.1016/j.encep.2021.08.002 · Cited by 6 · see citing works

Difficulty in Repurposing Selective Serotonin Reuptake Inhibitors and Other Antidepressants with Functional Inhibition of Acid Sphingomyelinase in COVID-19 Infection

Corre, P. L., & Loas, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.849095 · Cited by 6 · see citing works

Rubella virus chronic inflammatory disease and other unusual viral phenotypes in inborn errors of immunity

Kilich, G., Perelygina, L. M., & Sullivan, K. E. (2023) · Immunological Reviews · doi:10.1111/imr.13290 · Cited by 6 · see citing works

Fluoxetine and Sertraline Potently Neutralize the Replication of Distinct SARS-CoV-2 Variants

Thümmler, L., Beckmann, N., Sehl, C., Soddemann, M., Braß, P., Bormann, M., Brochhagen, L., Elsner, C., Hoertel, N., Cougoule, C., et al. (2024) · Viruses · doi:10.3390/v16040545 · Cited by 5 · see citing works

UCLA’s Molecular Screening Shared Resource: Enhancing Small Molecule Discovery with Functional Genomics and New Technology

Damoiseaux, R. D. (2014) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207317666140323134621 · Cited by 6 · see citing works

Emergence of Fluoxetine-Resistant Variants during Treatment of Human Pancreatic Cell Cultures Persistently Infected with Coxsackievirus B4

Alidjinou, E. K., Bertin, A., Sané, F., Caloone, D., Engelmann, I., & Hober, D. (2019) · Viruses · doi:10.3390/v11060486 · Cited by 6 · see citing works

Doxycycline inhibits neurotropic enterovirus proliferation in vitro

Chi, F., Liu, X., Li, J., Guo, M., Zhang, Z., Zhou, H., Carr, M. J., Li, Y., & Shi, W. (2024) · Virus Research · doi:10.1016/j.virusres.2024.199388 · Cited by 5 · see citing works

2C protein of Enterovirus: key protein of viral replication and antiviral target

Kazzi, P. E., Yaacoub, C., Fajloun, Z., Vanelle, P., Decroly, É., Coutard, B., & Barral, K. (2023) · Virologie · doi:10.1684/vir.2023.1002 · Cited by 5 · see citing works

Computational Drug Repositioning and Elucidation of Mechanism of Action of Compounds against SARS-CoV-2Preprint

Napolitano, F., Gambardella, G., Carrella, D., Gao, X., & Dd, B. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2004.07697 · Cited by 6 · see citing works

New fluoxetine analogues as anti-enterovirus agents targeting 2C protein

Khemiri, S., Faucher, M. O., Bourg, S., Attoumani-Madi, S., Yaacoub, C., Touret, F., Farag, M., Vitorino, M. F., Bonnet, P., Vanelle, P., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118621 · Cited by 4 · see citing works

Development of a fluorescence resonance energy transfer–based intracellular assay to identify novel enterovirus 71 antivirals

Lu, W.-W., Kung, F.-Y., Deng, P.-A., Lin, Y.-C., Lin, C., & Kung, S. (2016) · Archives of Virology · doi:10.1007/s00705-016-3143-x · Cited by 4 · see citing works

Natural Products as a Paradigm for the Treatment of Coxsackievirus - induced Myocarditis

Khanna, M., Gautam, A., Rajput, R., & Sharma, L. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200129094516 · Cited by 4 · see citing works

Novel Antiviral Activity of Ethyl 3-Hydroxyhexanoate Against Coxsackievirus B Infection

Olasunkanmi, O. I., Mageto, J., Ntsigouaye, J. A., Yi, M., Fei, Y., Chen, Y., Chen, S., Xu, W., Lin, L., Zhao, W., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.875485 · Cited by 4 · see citing works

Antiviral candidates for enterovirus 71: targeting viral proteome and stage-specific lifecycle interventions

Chen, J., Zhao, T. T.-Q., Ji, M., & Xia, B. (2025) · Virology Journal · doi:10.1186/s12985-025-02966-6 · Cited by 3 · see citing works

Herpes Simplex Virus-1 Induced Serotonin-Associated Metabolic Pathways Correlate With Severity of Virus- and Inflammation-Associated Ocular Disease

Battaglia, D. M., Sanchez‐Pino, M. D., Nichols, C. D., & Foster, T. P. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.859866 · Cited by 3 · see citing works

Sensitive and high-throughput bioanalysis of fluoxetine and nor-fluoxetine in rabbit and human plasma using SPE-LC-MS/MS

Prasad, Y. D., Chhonker, Y. S., Chandasana, H., Laxman, T. S., Bala, V., Kanojiya, S., Ghatak, S., & Bhatta, R. S. (2015) · Analytical Methods · doi:10.1039/c5ay00891c · Cited by 3 · see citing works

Inverse Virtual Screening in Drug Repositioning: Detailed Investigation and Case Studies

Warrier, S. B., & Kharkar, P. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-31759-5_5 · Cited by 3 · see citing works

Construction of a subgenomic CV-B3 replicon expressing emerald green fluorescent protein to assess viral replication of a cardiotropic enterovirus strain in cultured human cells

Wehbe, M., Huguenin, A., Lévêque, N., Semler, B. L., Hamzé, M., Andréoletti, L., & Bouin, A. (2016) · Journal of Virological Methods · doi:10.1016/j.jviromet.2016.01.005 · Cited by 3 · see citing works

Construction and In Vitro and In Vivo Analysis of Coxsackievirus B4 Reporter Viruses: Attenuated Virulence but Highly Efficient for Antiviral Drug Screening and Evaluation

Liu, Q., Wang, H., Xuan, X., Liu, H., Tang, B., Zhou, Z., Zhang, L., Qiu, S., Li, X., Tian, X., et al. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70433 · Cited by 2 · see citing works

Bioinformatic Approaches for Repurposing and Repositioning Antibiotics, Antiprotozoals, and Antivirals

Xia, X. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816125-8.00023-7 · Cited by 1 · see citing works

Protective effects of psychiatric medications against COVID-19 mortality before vaccines

Machado‐Vieira, R., Krause, T. M., Jones, G. H., Teixeira, A. L., Shahani, L., Lane, S. D., Soares, J. C., & Truong, C. (2025) · PLoS ONE · doi:10.1371/journal.pone.0310438 · Cited by 1 · see citing works

Advances in Antiviral Drug Development Targeting Enteroviruses: From Viral Proteins to Host Factors

Lu, J., Li, C., Cui, W., Du, Y., Geng, J., & Zhang, W. (2026) · Viruses · doi:10.3390/v18040476 · Cited by 1 · see citing works

Targeting Picornavirus Nonstructural 2C Protein: Structure, Function, and Antiviral Discovery

Li, K., Fan, G., Zhang, W., & Wang, J. (2026) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6c00387 · Cited by 1 · see citing works

Onaylanmış Merkezi Etkili İlaçların Antiviral Aktivitesi: Bir Anlatı İncelemesi

Elhadi, E., Abdulaziz, L., Abdallah, E. A., ALNOOR, F. A. E. A., & Yousef, B. A. (2022) · Hacettepe University Journal of the Faculty of Pharmacy · doi:10.52794/hujpharm.1047842 · Cited by 1 · see citing works

Fluoxetine pharmacokinetics and tissue distribution quantitatively supports a therapeutic role in COVID-19 at a minimum dose of 20 mg per day

Eugene, A. R. (2022) · F1000Research · doi:10.12688/f1000research.53275.3 · Cited by 2 · see citing works

Evaluating the Potential of Repurposing Commercially Available Drugs for the Treatment of Viral Infections

McEwan, B. C. (2021) · Digital Commons - USU (Utah State University) · doi:10.26076/6f41-58d6

From repurposed drugs to pan-enterovirus and rhinovirus inhibitors

Bauer, L. (2021) · doi:10.33540/216

iPSCs for modeling coxsackievirus infection

Belkaya, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823808-0.00004-3

Pharmacology of novel approaches designed to target picornaviral infections

Hasan, O. (2021) · Open Access at Essex (University of Essex)

Antidepressants with antimicrobial activity? A promising therapeutic strategy

González, G. M., Montoya, A. M., Andrade-Torres, A., Becerril-García, M. A., & Treviño‐Rangel, R. D. J. (2022) · Medicina Universitaria · doi:10.24875/rmu.22000036

Current therapeutic strategies and novel antiviral compounds for the treatment of nonpolio enteroviruses

Suresh, A. J., & Dass, R. S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91814-5.00015-5

2C protein of Enterovirus: key protein of viral replication and antiviral target

Kazzi, P. E., Yaacoub, C., Fajloun, Z., Vanelle, P., Decroly, É., Coutard, B., & Barral, K. (2023) · Virologie · doi:10.1684/vir.2023.1001

Chapter 12. Fluoxetine and Fluvoxamine

Aboujaoude, E. N., Rosenbaum, J. F., Ionescu, D. F., & Koran, L. M. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as12

The potential of leritrelvir repositioning for the treatment of coxsackievirus B4 and common enterovirus infections

Liu, Q., Tang, B., Xuan, X., Wang, H., Liu, H., Zhang, L., Qiu, S., You, A., Mo, C., Li, X., et al. (2026) · Antiviral Research · doi:10.1016/j.antiviral.2026.106367

Etude des caractères génétiques des Entérovirus persistants dans les tissus cardiaques de sujets atteints de cardiomyopathie dilatée idiopathique

Bouin, A. (2015) · doi:10.70675/92a12c45z71a9z42b7zb1a6z36f26bf6bf8b

Etude de l’activité de réplication des formes de Coxsackievirus B3 complètes et tronquées dans la région 5’non codante dans un modèle de cardiomyocytes humains primaires en culture.

Wehbe, M. (2016) · doi:10.70675/1db0c342z1e9bz402dz94e5z5315ecd9c739

Identification d’échanges génétiques modulaires entre des populations d’ARN complets ou tronqués en région 5’non codante d’Entérovirus du groupe B dans des cardiomyocytes humains primaires : impact sur la pathogénèse des cardiomyopathies dilatées inexpliquées chez l’Homme

Gretteau, P.-A. (2018) · doi:10.70675/f4be6f18z80a8z47fcza5bfz0d10a6f6473c

Détection moléculaire des formes complètes et tronquées en région 5’non codante des Entérovirus et conséquences sur la réponse inflammatoire chez des patients souffrant de myocardite ou de cardiomyopathie dilatée

N’Guyen, Y. (2019) · doi:10.70675/cfed4bb1z1fd6z47e3z9a31zce9bf6bc90ad

Fluoxetine Inhibits Enterovirus Replication by Targeting the Viral 2C Protein in a Stereospecific Manner

Bauer, L., Manganaro, R., Zonsics, B., Strating, J. R. P. M., Kazzi, P. E., Lopez, M. L., Ulferts, R., van Hoey, C., Maté, M. J., Langer, T., et al. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00179 · Cited by 78 · see citing works

Selective Serotonin Reuptake Inhibitor Fluoxetine Inhibits Replication of Human Enteroviruses B and D by Targeting Viral Protein 2C

Ulferts, R., van der Linden, L., Thibaut, H. J., Lanke, K. H. W., Leyssen, P., Coutard, B., Palma, A. M. D., Canard, B., Neyts, J. H., & van Kuppeveld, F. J. M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02084-12 · Cited by 102 · see citing works

Fluoxetine Can Inhibit SARS-CoV-2 In Vitro

Dechaumes, A., Nekoua, M. P., Belouzard, S., Sané, F., Engelmann, I., Dubuisson, J., Alidjinou, E. K., & Hober, D. (2021) · Microorganisms · doi:10.3390/microorganisms9020339 · Cited by 42 · see citing works

New fluoxetine analogues as anti-enterovirus agents targeting 2C protein

Khemiri, S., Faucher, M. O., Bourg, S., Attoumani-Madi, S., Yaacoub, C., Touret, F., Farag, M., Vitorino, M. F., Bonnet, P., Vanelle, P., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118621 · Cited by 4 · see citing works

Synthesis and antiviral effect of novel fluoxetine analogues as enterovirus 2C inhibitors

Manganaro, R., Zonsics, B., Bauer, L., Lopez, M. L., Donselaar, T., Zwaagstra, M., Saporito, F., Ferla, S., Strating, J. R. P. M., Coutard, B., et al. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104781 · Cited by 29 · see citing works